Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Biologicals. 2019 May 23;60:1–7. doi: 10.1016/j.biologicals.2019.05.005

Table 4.

Identified questions that could be addressed in laboratory studies in populations after natural influenza infections and/or vaccination with adjuvanted pandemic vaccines.

• What are the kinetics of the decay of NS1 antibodies following a natural influenza infection?
• Is there a difference in the immune response to a natural influenza infection or influenza vaccination in individuals expressing the HLA-DQB1*06:02 allele compared to other HLA types?
• Is the HLA-DQB1*06:02 allele linked to both vaccine or wild type virus associated narcolepsy?
• Is there a difference in the immune response to an adjuvanted vs a nonadjuvanted influenza vaccination in individuals expressing the HLA-DQB1*06:02 allele compared to other HLA types?
• Could questions about the HLA relationship be assessed using peripheral blood mononuclear cells (PBMC) stimulated with various pandemic strains and measurement of T-cell responses based on HLA status?
• Could bio-banked sera and PBMC from confirmed natural H1N1 infections be analyzed based on HLA status and could new clinical studies with PBMC stimulation or antibody measurements following vaccination be assessed based on HLA status?
• What was the role of the different vaccine components for pathogenesis of narcolepsy/cataplexy?
• What differences in the antigen content and related immune response was observed following vaccination with Pandemrix and Arepanrix?